1-3 of 3
Ana Paula Torres Cardoso
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 866.
https://doi.org/10.1182/blood-2023-182100
Published: 2023
Journal Articles

ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in the Chronic Phase

Nobuko Hijiya, Shruti Kapoor, Matthias Hoch, Laurence Descamps, Vishal Dhamal, Ana Paula Torres Cardoso
Journal: Blood
Blood (2023) 142 (Supplement 1): 6387.
https://doi.org/10.1182/blood-2023-185535
Published: 2023
Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio
Journal: Blood
Blood (2022) 140 (Supplement 1): 195–197.
https://doi.org/10.1182/blood-2022-167177
Published: 2022